曼凯德制药与创新生物公司合作, 在印度销售癌症免疫疗法辛提利马布. Mankind Pharma partners with Innovent Biologics to sell cancer immunotherapy sintilimab in India.

曼凯德制药与创新生物合作, 在印度独家授权和销售先进的PD-1免疫疗法Sintilimab. Mankind Pharma has partnered with Innovent Biologics to exclusively license and sell sintilimab, an advanced PD-1 immunotherapy, in India. 中国称为TYVYT的辛提利马布在治疗各种癌症方面显示出显著的效力和安全性。 Sintilimab, known as TYVYT in China, has shown significant effectiveness and safety in treating various cancers. 该伙伴关系旨在改善印度获得创新癌症治疗的机会,由人类制药公司负责登记和销售,创新公司负责管理制造和供应。 The partnership aims to improve access to innovative cancer treatments in India, with Mankind Pharma handling registration and sales, while Innovent manages manufacturing and supply.